Skip to main content
. 2023 Sep 13;11(9):e007002. doi: 10.1136/jitc-2023-007002

Figure 1.

Figure 1

VIII produces Tscm and Tcm-enriched AUTO1 CAR-T products (A) Schema of CAR T-cell manufacturing process. (B) Total T-cell fold expansion throughout manufacture, ±SEM. (C) AUTO1 CAR T-cell transduction at end of manufacture day 8, ±SD/individual data points. (D) Graphical representation of Tn (CCR7+/CD45RA+), Tcm (CCR7+/CD45RA−), Te (CCR7−/CD45RA−) and Tte (CCR7−/CD45RA+) subsets in CD4 and CD8 CAR T-cells determined by flowcytometry, ±SD at end of manufacture day 8. (E) Percentage CD95+ positive, sub gated from Tn population throughout manufacture, depicting individual data points. (F) Representative flowcytometry plots from one donor demonstrating CCR7/CD45RA staining in T-cell starting material and subsequently in CAR CD8s throughout manufacture. (G) Percentage CD27+/CD28+ and IL2+/Granzyme− in CD4/8 CAR T-cells at end of manufacture, determined by flowcytometry, graphs depicting individual data points. (B-E/G) n=6, Two tailed Mann-Whitney U test, ns p>0.05. *p<0.05 and **p<0.01. CAR, chimeric antigen receptor.